Genome-scale CRISPR screens identify host factors that promote human coronavirus infection

Abstract

Background The COVID-19 pandemic has resulted in 275 million infections and 5.4 million deaths as of December 2021. While effective vaccines are being administered globally, there is still a great need for antiviral therapies as antigenically novel SARS-CoV-2 variants continue to emerge across the globe. Viruses require host factors at every step in their life cycle, representing a rich pool of candidate targets for antiviral drug design. Methods To identify host factors that promote SARS-CoV-2 infection with potential for broad-spectrum activity across the coronavirus family, we performed genome-scale CRISPR knockout screens in two cell lines (Vero E6 and HEK293T ectopically expressing ACE2) with SARS-CoV-2 and the common cold-causing human coronavirus OC43. Gene knockdown, CRISPR knockout, and small molecule testing in Vero, HEK293, and human small airway epithelial cells were used to verify our findings. Results While we identified multiple genes and functional pathways that have been previously reported to promote human coronavirus replication, we also identified a substantial number of novel genes and pathways. The website https://sarscrisprscreens.epi.ufl.edu/ was created to allow visualization and comparison of SARS-CoV2 CRISPR screens in a uniformly analyzed way. Of note, host factors involved in cell cycle regulation were enriched in our screens as were several key components of the programmed mRNA decay pathway. The role of EDC4 and XRN1 in coronavirus replication in human small airway epithelial cells was verified. Finally, we identified novel candidate antiviral compounds targeting a number of factors revealed by our screens. Conclusions Overall, our studies substantiate and expand the growing body of literature focused on understanding key human coronavirus-host cell interactions and exploit that knowledge for rational antiviral drug development.

SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells

“…However, our findings that endogenous IFITM expression is critical for efficient replication of genuine SARS-CoV-2 in human lung and gut cells ( 4 ) are not contradicted by experimental evidence since inhibitory effects of IFITMs were generally observed under more artificial conditions. Notably, our results are in line with the recent identification of IFITM proteins as SARS-CoV-2 dependency factors in Vero E6 cells ( 52 ). It has been previously shown that IFITMs promote infection by human coronavirus OC43 ( 10 ), and recent data suggest that IFITM1 and -3 promote infection by herpesviruses and hepatitis B and D viruses ( 53 , 54 ).…”

Phenotype-driven identification of drug targets for post-COVID-19 anosmia

“…Notably, one study recently screened a number of drugs in vitro against human coronaviruses, including an inhibitor of FGFR1-3 approved for various lung disease indications such as idiopathic pulmonary fibrosis, which showed only “moderate” inhibition of SARS-CoV-2 cytotoxicity 29 . However, we do not draw conclusions either way from this result, as the mechanism of action to address acute infection may be different from the mechanism of action needed to address post-acute symptoms (as in the case of NRP1, above).…”

Molecular Virology of SARS-CoV-2 and Related Coronaviruses

“…The three above-described genes may be implicated in vesicle formation during autophagy. Grodzki et al ( 165 ) also identified TMEM41B and RAB7A . They demonstrated that CCZ1 and EDC4 were required for SARS-CoV-2 and HCoV-OC43 infection in CCZ1 or EDC4 knockdown cells.…”